Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 23Neoplasms 14Neoplasm Metastasis 14Glioblastoma 14Prostatic Neoplasms 13Breast Neoplasms 11Brain Neoplasms 11Sarcoma 10Lymphoma, Non-Hodgkin 10Kidney Neoplasms 10Endometrial Neoplasms 10Melanoma 9Lymphoma, Mantle-Cell 9Gliosarcoma 8Multiple Myeloma 7Glioma 7Ovarian Neoplasms 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Oligodendroglioma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Central Nervous System Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rhabdomyosarcoma 4

Interventions

cobimetinib 2trametinib 1temsirolimus 1dabrafenib 1Vemurafenib 1Valproic Acid 1Specimen Handling 1Sirolimus 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunoglobulin G 1Disulfides 1Cetuximab 1Biopsy 1Bevacizumab 168Ga-pentixafor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Erdheim-Chester Disease × temsirolimus × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡